Introduction to Brazilian Guidelines to Diagnosis, Treatment, and Monitoring for Gaucher Disease, Fabry Disease, Mucopolysaccharidosis I, and Pompe Disease

References 

1. Applegarth DA, Toone JR, Lowty RB. Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics. 2000;105:10
2. Meikle PJ, Hopwood JJ. Lysosomal storage disorders: emerging therapeutic options require early diagnosis. Eur J Pediatr. 2003;162:S34–S37
   • CrossRef
3. Schmitz J, Poll LW, Dahl SV. Therapy of adult Gaucher disease. Haematologica. 2007;65:37–42
4. Beutler E, Grabowski GA. Gaucher disease. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001;p. 3635–3668
5. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001;p. 3733–3774
6. Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid-α- glucosidase (acid maltase) deficiency. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001;p. 3389–3420
7. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001;p. 3421–3452
8. Beutler E. Lysossomal Storage diseases: natural history and ethical and economic aspects. Mol Genet Metab. 2006;88:208–215
   • MEDLINE
   • CrossRef
9. Beck M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet. 2007;121:1–22
   • CrossRef